



\$150 Million
Follow-On Offering

LEERINK 
PARTNERS
Joint Bookrunner
January 2024

Leerink Partners Serves as Joint Bookrunner for Viridian Therapeutics' (Nasdaq: VRDN) \$150 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched and priced on January 17th
- Consisted of 7,142,858 shares of common stock at a price of \$21.00 per share
- Viridian intends to use the net proceeds from this offering, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes.
- This is Leerink Partners' 3rd equity offering for Viridian and 4th equity offering in 2024.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

MIAMI
1395 Brickell Avenue
Suite 800
Miami, FL 33131

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111